


CHANGING THE WORLD, ONE PATIENT AT A TIME TM



- A clinical stage pharmaceutical company developing an Anti-Cancer treatment with light activated PhotoDynamic Compounds ("PDC") and their associated drug formulation.
- Fully launched Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study.
- Focused on becoming the next standard of care for treating

Anti-Cancer Technology ("ACT") Development

2011

- Licenced TLD-1433 PDC Drug for Anti-Cancer Therapy¹
- ·Successful pre-clinical results for NMIBC

2016

- •US patent protecting of unique PDC, TLD-14332
- Commenced Phase Ib NMIBC Clinical Study in human patients
- Demonstrated PDC application in various cancer indications GlioBlastoma Multiforme

- ·Completed \$1.4 M private placement equity financing (January, 2019)
- Oversubscribed Prospectus Offering \$17 M (August, 2019)
- Successful results from Phase lb 67% Complete Response with 2 patients cancer-free for 540 days
- Currently enrolling and treating for Phase II NMIBC Clinical Study
- Submitted Investigational New Drug application to FDA (September, 2019)

TSX Venture 50 Company in Clean Technology & Life Sciences

540

Days cancer-free status achieved by 2 patients in Phase Ib NMIBC study

67%

Response rate in Phase Ib NMIBC study

Patients treated in Phase II NMIBC study, to

Canadian oncology sites enrolled for Phase II NMIBC. to date

Cancer indications evaluated in preclinical studies

Owned and Licensed Patents

Patents Pending, strengthening **Intellectual Property**

Peer-Reviewed **Pre-clinical Studies**



67% Complete Response rate at 540 days (Phase Ib)





Willingness to pay for treatment

Jul 2019 Oct 2019 Mar 2020

Capital Structure on the Venture⁵ TSXV:TLT: OTCQB:TLTFF

Common Share Price: C\$ 0.285 Market Capital: C\$ 58 M


Shares Outstanding: 204,275,375


Warrants: 91,814,705 Options: 16,920,000


Shares Fully Diluted: 313,010,080

Insider Ownership: 7% (9.3% fully diluted)

52 Week Range: C\$ 0.21 - 0.61







Drug + Laser Light Device = Anti-Cancer Treatment for NMIBC

(TLC-3200)

(1) McFarland – Theralase Licence Agreement, Dated: September 11, 2011
(2) U.S. Patent Nos. 9,345,769 and 9,676,806 and Canadian Patent No. 2,883,068 patents for "Metal-Based Thiophene Photodynamic Compounds and Their Use"
(3) 2025 estimated bladder cancer market (US, France, Germany, Italy, Spain, UK & Japan). Source: Global Data: Bladder cancer market size to more than triple to over \$1.1 billion by 2025, April 2017.
(4) Willingness to pay per quality adjusted life year (QALY) for competitor drug, Pembrolizumab. Source: Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer, July 2018
(5) Stock information is provided by https://web.tmxmoney.com, as of February 25 2020

(TLD-1433)